Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer
- PMID: 15853731
- DOI: 10.2174/1566523053544272
Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer
Abstract
Dendritic cells (DCs) are the most effective antigen presenting cells (APCs) to elicit both primary and secondary T-cell response that is critical for antitumor immunity and elimination of intracellular pathogens. Therefore, DCs pulsed ex vivo with antigens have the potential used as cell-based vaccines against tumors. Viral vectors derived from adenoviruses have been extensively used to pulse DCs ex vivo by delivering genes encoding immunomodulatory molecules and tumor antigens to DCs since these vectors are relatively safe, effective in inducing the maturation of DCs, and can accommodate large expression cassettes encoding antigens. One of the hurdles for gene delivery to DCs by adenovirus (Ad) vectors, however, is low transfection efficiency of DCs due to the paucity of Ad receptor on DCs. To overcome this obstacle, targeted Ad vectors have been made by modifying viral capsid proteins. These targeted Ad vectors not only enhance the gene delivery to DCs, but also allow in vivo gene delivery to DCs, thus avoiding ex vivo manipulation of DCs.
Similar articles
-
Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.Cancer Res. 2000 Oct 1;60(19):5456-63. Cancer Res. 2000. PMID: 11034088
-
Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.Cancer Res. 2001 Nov 1;61(21):7913-9. Cancer Res. 2001. PMID: 11691812
-
Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.J Virol. 2004 Mar;78(5):2572-80. doi: 10.1128/jvi.78.5.2572-2580.2004. J Virol. 2004. PMID: 14963160 Free PMC article.
-
Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.Cell Res. 2006 Mar;16(3):241-59. doi: 10.1038/sj.cr.7310032. Cell Res. 2006. PMID: 16541123 Review.
-
Advances in dendritic cell-based vaccine of cancer.Cancer Biother Radiopharm. 2002 Dec;17(6):601-19. doi: 10.1089/108497802320970217. Cancer Biother Radiopharm. 2002. PMID: 12537664 Review.
Cited by
-
Adenovirus: the first effective in vivo gene delivery vector.Hum Gene Ther. 2014 Jan;25(1):3-11. doi: 10.1089/hum.2013.2527. Hum Gene Ther. 2014. PMID: 24444179 Free PMC article. Review. No abstract available.
-
Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy.Biomedicines. 2019 Aug 19;7(3):61. doi: 10.3390/biomedicines7030061. Biomedicines. 2019. PMID: 31430920 Free PMC article. Review.
-
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology. 2022 Jul 4;11(1):2096363. doi: 10.1080/2162402X.2022.2096363. eCollection 2022. Oncoimmunology. 2022. PMID: 35800158 Free PMC article.
-
Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.Cancer Immunol Immunother. 2007 Oct;56(10):1615-24. doi: 10.1007/s00262-007-0307-2. Epub 2007 Mar 14. Cancer Immunol Immunother. 2007. PMID: 17356843 Free PMC article.
-
Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.Genes Dis. 2017 Jun;4(2):43-63. doi: 10.1016/j.gendis.2017.04.001. Epub 2017 Apr 27. Genes Dis. 2017. PMID: 28944281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
